Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Experimental therapies

Investigator-initiated cancer trials with INDs for approval in Japan

Nature Reviews Clinical Oncology volume 7, pages 127–128 (2010)Cite this article

Subjects

In Japan, it is quite rare for an investigator to submit an investigational new drug application to initiate a clinical trial and obtain approval of a drug on the basis of clinical trial results. This means that development of new therapies is currently driven almost entirely by pharmaceutical companies as opposed to independent investigators. Here, we provide our perspective on the reasons for this situation and advocate investigator-initiated cancer drug development as a means of increasing access to better therapies for Japanese cancer patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) Guidance for Industry: IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer [online], (2004).

  2. Fujiwara, Y. Future perspectives of registration-directed clinical trials from the standpoint of large academic hospital [Japanese]. Farumashia 44, 789–794 (2008).

    Google Scholar 

  3. UMIN Clinical Trials Registry [online], (2009).

  4. JMACCT Clinical Trial Information Registration [online], (2009).

  5. US Department of Health and Human Services, Food and Drug Administration, Office of Regulatory Affairs: Guidance for Industry: Guideline for the Monitoring of Clinical Investigations [online], (1998).

  6. American Society of Clinical Oncology. Reimbursement for cancer treatment: Coverage of off-label drug indications. J. Clin. Oncol. 19, 3206–3208 (2006).

  7. Tsuji, K. & Tsutani, K. Follow the leader. Nature 453, 851–852 (2008).

    Article  CAS  Google Scholar 

  8. Trimble, E. L. et al. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J. Clin. Oncol. 27, 5109–5114 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, 35 Shinano-machi, Shinjuku-ku, 160-8582, Tokyo, Japan

    Chiyo K. Imamura

  2. Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Rockville, 20852, MD, USA

    Naoko Takebe

  3. Department of Breast Surgical Oncology, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, 104-8560, Tokyo, Japan

    Seigo Nakamura

  4. Division of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, 35 Shinano-machi, Shinjuku-ku, 160-8582, Tokyo, Japan

    Hideyuki Saya

  5. Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, 77030, TX, USA

    Naoto T. Ueno

Authors
  1. Chiyo K. Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoko Takebe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seigo Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideyuki Saya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoto T. Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoto T. Ueno.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Imamura, C., Takebe, N., Nakamura, S. et al. Investigator-initiated cancer trials with INDs for approval in Japan. Nat Rev Clin Oncol 7, 127–128 (2010). https://doi.org/10.1038/nrclinonc.2010.13

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.13

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing